Breast cancer bone micrometastases can remain asymptomatic for years before progressing into overt lesions. The biology of this process, including the microenvironment niche and supporting pathways, is unclear. We find that bone micrometastases predominantly reside in a niche that exhibits features of osteogenesis. Niche interactions are mediated by heterotypic adherens junctions (hAJs) involving cancer-derived E-cadherin and osteogenic N-cadherin, the disruption of which abolishes niche-conferred advantages. We elucidate that hAJ activates the mTOR pathway in cancer cells, which drives the progression from single cells to micrometastases. Human data set analyses support the roles of AJ and the mTOR pathway in bone colonization. Our study illuminates the initiation of bone colonization, and provides potential therapeutic targets to block progression toward osteolytic metastases.
In Brief
Wang et al. model breast cancer bone micrometastasis and identify an osteogenic niche that supports this process. Heterotypic adherens junctions form between cancer cells and stromal cells in these niches and activate mTOR to promote micrometastasis progression.
INTRODUCTION
When diagnosed in the clinic, breast cancer bone metastases are primarily osteolytic and driven by a vicious cycle between cancer cells and osteoclasts (Ell and Kang, 2012; Kozlow and Guise, 2005; Mackiewicz-Wysocka et al., 2012; Mundy, 2002; Weilbaecher et al., 2011) . Bisphosphonates (Diel et al., 1998) and denosumab (Lipton et al., 2007) have been used to inhibit
Significance
In advanced stages, breast cancer bone metastases are driven by paracrine crosstalk among cancer cells, osteoblasts, and osteoclasts, which constitute a vicious osteolytic cycle. Current therapies targeting this process limit tumor progression, but do not improve patient survival. On the other hand, bone micrometastases may remain indolent for years before activating the vicious cycle, providing a therapeutic opportunity to prevent macrometastases. Here, we show that bone colonization is initiated in a microenvironment niche exhibiting active osteogenesis. Cancer and osteogenic cells form heterotypic adherens junctions, which enhance mTOR activity and drive early-stage bone colonization prior to osteolysis. These results reveal a strong connection between osteogenesis and micrometastasis and suggest potential therapeutic targets to prevent bone macrometastases. 
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this vicious cycle and achieved a significant delay of metastasis progression, but they have not improved patient survival (Coleman et al., 2008; Mackiewicz-Wysocka et al., 2012; Onishi et al., 2010) . Recent studies have elucidated roles for various pathways in osteolytic bone metastasis, including TGF-b, hypoxia, Hedgehog, Integrin, and Notch (Bakewell et al., 2003; Buijs et al., 2011; Dunn et al., 2009; Heller et al., 2012; Kang et al., 2003; Sethi et al., 2011) . Molecular and cellular events that initiate the vicious cycle have also been identified. Specifically, cancer-cell-derived and expressed VCAM-1 has been shown to engage osteoclast progenitor cells and accelerate their differentiation, which may represent a critical step for microscopic bone metastases to progress into clinically significant lesions (Lu et al., 2011) . These findings provide further therapeutic targets to intervene in the osteolytic cycle.
In contrast to our knowledge of overt bone metastases, we know much less about microscopic bone metastases prior to the osteolytic cycle. In fact, such micrometastases may remain asymptomatic for a prolonged period of time before being reactivated to progress, a clinical phenomenon often referred to as metastasis dormancy (Aguirre-Ghiso, 2007) . Disseminated tumor cells (DTCs) in the bone marrow have been detected in patients that appear tumor free (Pantel et al., 2008 (Pantel et al., , 2009 . DTCs may establish their first foothold in the bone marrow by competing with hematopoietic stem cells for the niche occupancy (Shiozawa et al., 2011) . However, it remains elusive how cancer cells interact with the niche cells to begin colonization and whether there are intermediate stages between solitary DTCs and osteolytic metastases.
RESULTS

Intrailiac Artery Injection of Breast Cancer Cells Enriches for Microscopic Bone Lesions, Allowing Inspection of Preosteolytic Bone Colonization
We used intrailiac artery (IIA) injection to monitor early-stage bone colonization. This approach selectively delivers cancer cells to hind limb tissues and bone through the external iliac artery ( Figure 1A ) without damaging local tissues. We characterized this approach and compared it to intracardiac (IC) injection, a widely used technique in bone metastasis research. Specifically, we examined the following: (1) the course of metastatic colonization, (2) organ distribution of disseminated tumor cells, and (3) the potential Darwinian selection process. Cell lines of different subtypes were analyzed to reveal the diverse metastatic behaviors of breast cancer cells.
MDA-MB-231 cells (ER À /PR À /Her2 À ) are known to metastasize aggressively in xenograft models. Single cancer cells were readily detectable in the bone marrow immediately after IIA injection ( Figure 1B ). Strong bone lesions developed within 40 days, as indicated by the bioluminescence (BL) signals ( Figure 1C ). We stained the bone lesions for tartrate-resistant acid phosphatase (TRAP), a hallmark of activated osteoclasts, to ask if the lesions would progress fully. Positive staining was markedly increased compared to tumor-free counter-lateral legs of the same animals, indicating ongoing osteolytic cycle ( Figure 1D ). Compared to IC injection, cancer cells injected via IIA are predominantly localized to the hind limb bones, sparing lungs, the brain, and other soft tissue organs excessive tumor burdens (Figures 1E and 1F) . A larger quantity of cancer cells (e.g., 5 3 10 5 MDA-MB-231 cells) can be injected through IIA without causing thrombosis-related deaths to animals ( Figure 1F ), a phenomenon often seen during IC injection. As a result of the highly targeted delivery of cancer cells, full body BL signals strongly correlated with those from dissected bones ( Figure S1A available online). We then designed a clonal competition assay to ask if IIA-injected cancer cells encounter a Darwinian selection process. We admixed RFP-tagged parental MDA-MB-231 cells with a GFP-tagged bone-tropic clone MDA-MB-231 SCP28 (Minn et al., 2005 ) at a 1:1 ratio. In 2 weeks, the GFP + /RFP + shifted dramatically from 1:1 to >10:1 (Figures 1G and S1B) in both IIA and IC models, reflecting the Darwinian selection process during bone colonization. We then examined MCF-7 cells (ER + /PR + /Her2 À ), a cell line experimentally more indolent than MDA-MB-231 cells. IIA injection delivered MCF-7 cells primarily to the hind limb. IC injection only resulted in detectable bone colonization in two of five mice, whereas IIA injection gave rise to bone lesions in all five animals examined (Figures S1C and S1D) . The kinetics of MCF-7 bone colonization was slow in the first 2-4 weeks, but accelerated afterward ( Figure 1H ). We used an inducible H2B-GFP system to track the proliferation history of individual cells ( Figure S1E ; Fuchs and Horsley, 2011) . Although some cancer cells progressed to microscopic lesions in 2 weeks, a proportion stayed positive for H2B-GFP ( Figure 1I ). Ki67 staining on consecutive sections confirmed that these H2B-GFP + cells were not proliferative ( Figure 1I ). Therefore, the fates of cancer cells vary after their arrival in the bone marrow. There was no enrichment of TRAP staining in or surrounding tumor lesions on day 28 or earlier ( Figure 1J ). Starting on day 35, some lesions showed increased TRAP staining, indicating a transition toward the osteolytic cycle ( Figures 1J and 1K Figure 2B ). The frequencies of ALP + and Col-I + cells were 10% and 3% in the tumor-free metaphysis area, suggesting enrichment of these cells in the niche. The absolute numbers of each cell type also were counted ( Figure 2C ), leading to the same conclusion. Second, we assessed the proportion of lesions that had at least two cells of each type in the niche ( Figure 2D ). All niches contained ALP + and Col-I + cells, strongly suggesting that these cells are associated with the progression to multicell lesions. CTSK + cells were only found in a minority of niches in MCF-7, MDA-MB-361, and 4T1 models. In the 4TO7 model, CTSK + cells were found in all niches examined with a relatively low frequency in each niche ( Figures 2B and 2C ). We also examined cells expressing Nestin, CD31, aSMA, and CD45 ( Figure S2A ). None of these cell types were nearly as frequent as ALP + and
Col-I + cells.
Taken together, these findings suggest that ALP + and Col-I + cells are the primary components of the microenvironment niche in early stage bone colonization. In contrast, the abundance of CTSK + osteoclasts and other cell types in the niche is relatively minor.
The Microenvironment Niche of Microscopic Bone Lesions Exhibits Features of Osteogenesis
ALP and Col-I are associated with osteogenesis, or bone formation, and have been used as cell markers of osteoblasts (Lynch et al., 1995; Pittenger et al., 1999) . Several lines of evidence indicate that the niche of the microscopic lesions involves an active osteogenesis process. First, a variable proportion of the niche cells expressed RUNX2 and Osterix (Osx) ( Figures 2E, 2F , and S2B), master regulators of osteogenesis. In contrast, the chondrogenesis regulator SOX9 was not detected in the niche (Figure 2G) . Second, the niche cells displayed active canonical WNT signaling, as indicated by the nuclear localization of b-catenin ( Figure 2H , open arrows) and LEF-1 expression ( Figure S2C ). WNT signaling is a major driving force of osteogenesis (Baron and Kneissel, 2013; Long, 2012) . Of note, b-catenin was also observed along the membrane, suggesting adherens junctions (AJs) ( Figure 2H , solid arrows). Third, histomorphometry analyses showed a 3-to 5-fold higher osteoid (newly formed osteoblasts) coverage in areas directly adjacent to the lesions ( Figures 2I and 2J ). In contrast, the osteoclast coverage was not affected (Figures 2J and S2D ). Collectively, these findings Figure S3B ). When the two cell types were separated using Boyden Chamber, the promoting effects were diminished ( Figure S3C ), suggesting the necessity of direct cell-cell contact. We next performed cocultures in 3D suspension conditions widely used in mammosphere assays. Interestingly, cancer cells and osteogenic cells formed a heterotypic organoid structure with an oncogenic shell and an osteogenic core ( Figure 3A ). This structure was not observed with the same cancer cells labeled with another color or with RAW264.7 cells ( Figure 3A ). Compared to the osteogenic niche structure in vivo (Figure 2A ), the relative positioning (or polarity) of cancer and osteogenic cells was inverted in the heterotypic organoids. However, the organoids did recapitulate the extensive and direct contact between two cell types. Both MSC and FOB1.19 cells were able to accelerate tumor cell proliferation, with the effects increasing over time ( Figure 3B ). The effects of the monocytes were modest ( Figure 3B ), even after they differentiated into osteoclasts. Cancer cells in the heterotypic organoids exhibited a large increase of Ki67 staining, whereas the osteogenic cells in this structure appeared to differentiate with increased ALP expression ( Figure 3C ). The effects of MSCs on MCF-7 cells can be reproduced in a number of other cancer cell models as well as using more differentiated osteogenic cells ( Figure 3D ).
Provision of Exogenous MSCs Promotes Bone Colonization In Vivo
To ask if osteogenic cells promote cancer cell proliferation in the bone microenvironment, we performed IIA injection using admixed cancer cells and osteogenic cells at a 1:1 ratio. Upon arrival at the bone marrow, about 50% of MCF-7 cells paired with MSCs via direct cell-cell contact ( Figure 3E ). The exogenous MSCs significantly decreased the latency and increased the tumor burden of bone colonization ( Figures 3F and 3G) . Similar results were also obtained using MDA-MB-361 cells ( Figures  3H and S3D ) and 4TO7 cells ( Figure 3I ). For the latter, the coinjection was performed on immunocompetent BALB/c mice.
Cancer Cells and Osteogenic Cells Form hAJs Using E-cad and N-cad The direct and tight contact between microscopic lesions and the osteogenic niche led us to hypothesize that they form cellcell junctions. The cancer cells used in previous experiments expressed variable levels of E-cadherin (E-cad) ( Figure S4A ). Interestingly, E-cad in cancer cells appears to be required for effects of osteogenic cells, as cancer cell lines without E-cad could not gain proliferative advantages from cocultured MSCs ( Figure S4B ). On the other hand, the osteogenic cells primarily expressed N-cadherin (N-cad) and OB-cadherin (OB-cad), but not E-cad. Since N-cad and E-cad have been reported to form heterotypic adherens junctions (E-N hAJs) in vitro (Straub et al., 2011) , we first focused on the interaction between these two cadherins. Several lines of evidence support the formation of E-N hAJs. First, costaining of E-cad and N-cad in heterotypic organoids confirmed that they are exclusively expressed in cancer cells and osteogenic cells, respectively, and are colocalized to the border of the two cell types ( Figure 4A , arrows), where b-catenin is also localized ( Figure 4B ). Likewise, in the bone lesions, E-cad, N-cad, and b-catenin were aligned to the cancer-niche interface as well (Figures 4C and 2H) . Second, a biochemical assay showed that E-cad was coimmunoprecipiated with N-cad, indicating that they physically interact with each other in vitro ( Figure S4C ). Third, a proximity ligation assay (PLA), which reflects molecular interaction in situ (Sö derberg  et 
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normal bone ( Figure S4E ). We also asked if endothelial cells are another major source of N-cad. However, endothelial cells only accounted for a minority of cells in the niche ( Figure S2A ) and only a small proportion of N-cad was colocalized with the endothelial cell marker, CD31 ( Figure S4E ). Taken together, these data strongly support that the E-N hAJ mediates the interaction between cancer cells and osteogenic cells in vitro and in vivo.
Evidence Supporting the Role of E-N hAJs in Clinical Specimens
In the clinic, bone metastases most frequently occur in tumors of the luminal subtype, which are typically ER + (Kennecke et al., 2010; Smid et al., 2008) . E-cad is the major cadherin in this subtype ( Figure S4F ; Perou et al., 2000; Sørlie et al., 2001) . Our data suggest that E-cad in cancer cells mediates tumor-niche interaction, and might provide an explanation for the bone-tropism of luminal breast cancer. Expression of E-cad is weakly but significantly associated with worse overall survival and distant metastasis-free survival in the METABRIC (Curtis et al., 2012) and Erasmus data sets (Smid et al., 2008) , respectively ( Figure S4G ). A further analysis revealed that E-cad is associated with bone metastasis specifically in the luminal subtype, which expresses a high level of E-cad ( Figures 4F and S4F ), but not in the basal subtype ( Figures S4F and S4H ). These results support the hypothesis that E-cad may mediate bone colonization if expressed in cancer cells, being the seeds of metastasis.
On the other hand, the soil of bone metastasis, namely the bone and bone marrow, is largely E-cad low or negative ( Figures  4C and S4I ). The osteogenic cells including MSCs highly express N-cad and OB-cad ( Figure S4A ). Thus, if AJs are required for cancer cells to colonize the bone, they are likely to be constituted by E-cad of cancer cells and N-cad or OB-cad of osteogenic cells.
The cadherin expression of human bone metastases retains the features of normal bone, in that N-cad and OB-cad are expressed at a higher level than metastases in other organs (Figure 4G) . This suggests that metastatic bone lesions are heavily infiltrated by osteogenic cells. E-cad is expressed at a slightly lower level ( Figure 4G ), which is counterintuitive because cancer cells in bone metastases are mostly ER + and expected to express E-cad (75% of bone metastases versus 47% of other metastases are ER + ). A plausible explanation is that the infiltrated mesenchymal cells, rich in N-cad and OB-cad but scarce in E-cad, may dilute the overall level of E-cad of the entire lesion. Indeed, at the transcriptomic level, bone metastases exhibit mesenchymal characteristics, as reported in previous studies (Zhang et al., 2013) . Bone metastases also differ from other metastases in their enhanced expression of constitutive AJ components including a-catenin, b-catenin, and p120-catenin, suggesting the prevalence of AJ machinery ( Figure 4H ). Taken together, these data support the importance of AJs in human bone metastases.
The hAJs Mediate the Cancer-Promoting Effects of the Osteogenic Niche
We used EGTA to titrate Ca 2+ and disrupt AJs. At 1 mM, EGTA significantly decreased cancer cell proliferation in the heterotypic organoids, but had little effect on mammospheres formed by only cancer cells, suggesting a selectively more stringent dependence on Ca 2+ of hAJs ( Figure 5A ). Antagonizing E-cad by a neutralizing antibody (anti-Ecad) or by inducible expression of dominant negative E-cad (DN-Ecad) (Nieman et al., 1999 ) both led to decreased cancer cell proliferation in the heterotypic organoids (Figures 5B, 5C, and S5A). We next perturbed N-cad in osteogenic cells by a neutralizing antibody (anti-Ncad) and siRNAs (si-Ncads). Both treatments resulted in decreased ability of osteogenic cells to promote tumor proliferation (Figures 5D, 5E, and S5B). In contrast, siRNAs against OB-cad did not have the same effect ( Figure S5C ). Finally, N-cad-coated plates conferred a stronger growth advantage to E-cad-expressing cancer cells compared to other recombinant cadherins ( Figures  5F and S5D ). Collectively, these results strongly argue that hAJs are required for the osteogenic-cell-conferred proliferative effects on cancer cells in vitro.
To test the importance of AJs in vivo, we administered antiEcad on animals receiving MCF-7 cells through IIA. This treatment significantly delayed early bone colonization (Figures 5G and 5H) , and resulted in microscopic lesions that appeared smaller and less proliferative ( Figure 5I ). Inducible expression of DN-Ecad achieved similar effects ( Figures 5J-5L ). The effects of DN-Ecad appeared to be specific to bone metastasis, as the inducible expression did not suppress orthotopic tumor growth ( Figure S5E ). Taken together, these results provide support for an important role of AJs in early-stage bone colonization.
Interaction between Osteogenic Cells and Cancer Cells Activates the mTOR Pathway in Cancer Cells
We performed a phospho-antibody array on the heterotypic organoids formed by MCF-7 cells and MSCs. Spheres of MCF-7 cells alone, MSCs alone, and their admixture were used as controls to delineate molecular reactions selectively elicited by direct MSC-cancer contact ( Figure 6A ). Among the total of 39 phosphoproteins, the phosphorylation on Ser235/236 of ribosomal protein S6 (pS6RP[S235/S236]) displayed a marked increase in the heterotypic organoids ( Figure 6A ). S6RP is a substrate of S6 kinase (S6K), which is in turn a direct substrate of the mTOR kinase. A more quantitative analysis of low-intensity signals of other phosphoproteins on the array revealed a 1.7-to 1.8-fold increase of pAKT(Ser473) and pAKT(T308) ( Figure S6A ).
To validate the activation of the AKT-mTOR pathway in the heterotypic organoids, we performed western blots to examine the phosphorylation status of AKT, S6K, and 4EBP1. Like S6, S6K and AKT were significantly activated ( Figure 6B ). We asked if the enhancement of mTOR activity occurs in cancer cells. MSCs exhibited a constitutively high level of p4EBP1(T37/T46), masking any alterations in cancer cells ( Figure 6B ). However, the S6K activity was exclusively restricted to the cancer cells in the heterotypic organoids ( Figure 6C ). A similar observation also was made using MC3T3 cells ( Figure S6B ). Taken together, these results indicate that the direct contact between cancer and osteogenic cells activates the mTOR pathway in cancer cells.
The Enhancement of mTOR Activity Requires hAJs
In Vitro and In Vivo EGTA abolished the osteogenic cell-induced increase of mTOR activity in cancer cells, and the abolishment was rescued by Ca 2+ (Figures 6D and S6C) . Similarly, induction of DN-Ecad also led to a reduction of pS6K(T389) ( Figure 6E ). N-cad depletion in osteogenic cells decreased their effects on the mTOR activity in cancer cells ( Figure 6F ). Finally, N-cad-coated plates stimulated the mTOR activity in cancer cells to a greater degree than E-cad and OB-cad ( Figure 6G ). These data strongly support that hAJs promote cancer cell proliferation via enhancing the activity of the mTOR pathway in cancer cells.
To validate the cellular source of the mTOR activity in heterotypic organoids, we examined the in situ IF staining of pS6K(T389) when E-cad in cancer cells was blocked by antiEcad ( Figure 6H ) or by the expression of DN-Ecad (Figure 6I ), or when N-cad in osteogenic cells was antagonized by antiNcad ( Figure 6J ) or by si-Ncad ( Figure 6K ). Under these conditions, pS6K(T389) signals remained exclusively to cancer cells and exhibited a significant decrease in intensity.
In vivo, IF staining of pS6K(T389) revealed robust mTOR signaling in multicell lesions ( Figure S6D, red arrows) . Very weak or no pS6K(T389) staining was detected in cancer cells that remain solitary or in loose clusters in the same field (Figure S6D, white arrow) , suggesting that the activation of mTOR accompanies bone metastasis progression from single cells to microscopic lesions. Both anti-Ecad or DN-Ecad treatment resulted in a lower pS6K(T389) level ( Figures 6L and 6M ) in the bone lesions, suggesting that the enhanced mTOR activity in cancer cells is dependent on their interaction with osteogenic cells via hAJs both in vitro and in vivo.
Inhibition of the mTOR Pathway Reversed the Osteogenic Cell-Conferred Growth Advantage
We transduced MCF-7 cells with shRNAs against Raptor or Rictor, the necessary components of mTOR Complexes 1 and 2, respectively ( Figure S7A ). The depletion of these proteins in cancer cells partially abolished the osteogenic cell-conferred growth advantage in 3D cocultures ( Figure S7B ). Furthermore, MCF-7 cells with Raptor or Rictor knockdown exhibited significantly decreased bone colonization in the preosteolytic stage ( Figure 7A ). In contrast, the orthotopic tumor growth was only modestly affected by the same shRNAs during the same timeframe ( Figure S7C ). Depletion of Raptor or Rictor in osteogenic cells did not affect their ability to promote cancer cell proliferation ( Figure S7D ). We then used mTOR inhibitors to achieve a more complete, pharmacological blockade of this pathway. Two inhibitors, Torin 1 (Thoreen et al., 2009 ) and rapamycin, without affecting the proliferation or survival of osteogenic cells ( Figure S7E ), potently reduced the osteogenic cell-conferred gowth advantage on cancer cells (Figures S7F and S7G ). In contrast, the MEK inhibitor, PD98085, failed to achieve the same effect ( Figure S7F ), arguing against a role of the MAPK pathway in this process. Torin 1 also abolished the N-cadinduced proliferation ( Figure S7H ), suggesting that mTOR mediates the downstream signaling of E-N hAJs.
In vivo treatment with Torin 1 or rapamycin significantly delayed bone colonization of MCF-7 cells ( Figure 7B ). Torin 1 treatment of 4TO7 bone lesions in BALB/c mice resulted in a similar effect ( Figure 7C ). Solitary disseminated cancer cells were largely Ki67-negative and cleaved caspase-3-negative in both treated and control groups, suggesting that these cells are quiescent and do not respond to Torin 1 ( Figure 7D , white arrows). This is consistent with the fact that solitary cancer cells in the bone marrow in general possess low mTOR activity ( Figures S6D and S7I ). Multi-cell lesions, on the other hand, exhibited decreased proliferation with Torin 1 treatment ( Figure 7D ), but the survival/apoptosis appeared unaffected. Interestingly, at later stages of bone colonization, although the mTOR activity remained high ( Figure S7I ), Torin 1 treatment no longer delayed bone colonization ( Figures 7D and S7J) . These results suggest that the bone colonization process may be dependent on the enhanced mTOR activity, specifically at the early stage when cancer cells are associated with the osteogenic niche. In later stages, although the mTOR activity might still be on, it may not be essential for the further progression of bone metastases.
The Increase of mTOR Activity Is Associated with Bone Metastasis Progression from DTCs in Human Breast Cancer We interrogated the mTOR activity in a previously published data set comprised of transcription profiles of human DTCs and overt bone metastases (Cawthorn et al., 2009 ). The mTOR activity was inferred using two signatures derived by profiling transcriptional responses of various cell line models to rapamycin and PP242 treatment . Like Torin 1, PP242 is a newly developed mTOR inhibitor targeting both mTORC1 and mTORC2 (Hsieh et al., 2010) . We first applied these signatures to the Cancer Genome Atlas database microarrays with matched reverse-phase protein array (RPPA) data (Cancer Genome Atlas Network, 2012), and confirmed their correlation with upstream regulators and downstream substrates of the mTOR pathway ( Figure 7E ). Using these signatures, we found that the predicted mTOR activity is significantly higher in bone metastases compared to in DTCs ( Figure 7F ), supporting that enhancement of mTOR activity is associated with bone metastasis progression.
The Osteogenic Niche of Spontaneous Bone Micrometastases
To validate our findings in spontaneous metastasis models, we used the 4T1.2 cell line, which was shown to give rise to spontaneous metastasis to bone and other organs ( Figure S8A ; Eckhardt et al., 2005) . In addition, we identified one tumor line derived from p53 null BALB/c mice (Herschkowitz et al., 2012) , termed 2208L, which spontaneously metastasizes to bone and bone marrow as indicated by tumor-specific PCR ( Figure S8B ). Both 4T1.2 and 2208L express E-cad ( Figure S8C ). We examined hind limb bones 2 weeks or 1 month after resection of orthotopic 4T1.2 or 2208L tumors, respectively ( Figure 8A ). All microscopic multicell lesions we could observe in the bone (n = 3) directly contacted ALP + and Col-I + cells, but not CTSK + cells ( Figures 8B and S8D) . Further experiments revealed that 4T1.2 spontaneous bone metastases exhibited positive pS6K(T389) staining ( Figure 8C ) and expressed E-cad that was colocalized with the N-cad of the niche ( Figure 8D ). We next investigated the effects of anti-Ecad and Torin 1 treatment on spontaneous bone metastases. Orthotopic 4T1.2 tumors were resected prior to the treatment with anti-Ecad ( Figure 8E ) or Torin 1 ( Figure 8F ). While anti-Ecad and Torin 1 significantly decreased bone metastases, they had little effect on lung metastasis ( Figures 8E and 8F ) or residual orthotopic tumors (Figure S8E) , suggesting bone specificity. Similar effects of Torin 1 treatment on 2208L bone lesions were observed using a qPCR-based approach. ( Figure S8F ). Taken together, these results strongly support the conclusion that hAJs and mTOR signaling drives early-stage bone colonization in both IIA and spontaneous models.
DISCUSSION
We have characterized the microenvironment niche of bone microscopic lesions, which is primarily comprised of cells in the osteoblast lineage and possess osteogenic potential (Figure 8G ). Our data showed that a substantial proportion of the osteogenic cells still express Osterix and RUNX2, markers of osteo-progenitor cells, suggesting an ongoing osteogenesis process. Thus, the microenvironment niche of bone micrometastases is dynamic. An important question is regarding the relationship between the osteogenic niche observed here with the long-proposed endosteal osteoblastic niche harboring hematopoietic stem cells (HSCs) (Calvi et al., 2003) . A previous study showed IC injection of prostate cancer cells increased HSC frequency in the blood, suggesting that cancer cells may compete against HSC for niches as the first foothold of bone colonization (Shiozawa et al., 2011) . Our data cannot directly test this hypothesis as the exact constitution and organization of the HSC niche remain largely uncertain. The answers to these questions need to be addressed in future studies. Our data indicate an important role of AJs in early-stage bone colonization. When E-cad-positive cancer cells disseminate to the bone and bone marrow as single cells, the first AJs they are able to form are likely to be E-N hAJs, because of the scarcity of E-cad and the abundance of N-cad in the microenvironment ( Figure 8G) . Thus, the formation of E-N hAJs may represent the first critical step of bone colonization. After the first few cell divisions, E-E homotypic junctions form between daughter cancer cells, which may contribute to fueling further progression, although, according to our data, E-N heterotypic AJs may still confer a stronger proliferative advantage. Other cadherins expressed in cancer cells also may be involved in heterotypic AJs. In fact, 4TO7 only expressed a minimal level of E-cad (Figure S4A) , which is consistent with previous studies (Korpal et al., 2011) . Correspondingly, the effects of E-cad neutralization were modest in 4TO7 coculture assays ( Figure S5A ), despite the similar dependency of these cells on osteogenic cell-derived N-cad ( Figure S5B ) and the mTOR pathway ( Figure S7F ). Thus, we cannot rule out the possibility that other cadherins contribute to the formation of hAJs with N-cad.
We found that the enhancement of the mTOR pathway is a consequence of E-N hAJs. The mTOR signaling has been implicated in resistance to endocrine therapies in ER + breast cancer (Boulay et al., 2005; Schiff et al., 2004) . A recent Phase III clinical trial on postmenopausal endocrine-resistant breast cancer revealed an increase in progression-free survival when Everolimus, a rapamycin analog, was used in combination with an aromatase inhibitor Exemestane (Baselga et al., 2012) . Of the patients in this trial, 76% had bone metastases, indicating that the mTOR inhibitor may efficiently inhibit the progression of metastatic colonization in bone. However, another Phase III trial using a different combination of rapalog and aromatase inhibitor as the first-line therapy failed to achieve the same efficacy (Wolff et al., 2013) . Thus, additional studies are required to understand how different mTOR inhibitors act on breast cancer of various subtypes, in distinct stages, at different sites, and with diverse treatment history. Our findings and experimental models should help facilitate the understanding of how mTOR functions to promote progression from single DTCs to microscopic bone metastases.
EXPERIMENTAL PROCEDURES Animal Studies
All animal work was done in accordance with a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee.
IIA Injection
Anesthetized mice were restrained on a plastic board. A 1.5 cm incision was made on the skin along the line between femoral and ilium bones. Blunt dissection was performed to separate muscles and reveal the common iliac artery. Cancer cells suspended in 0.1 ml PBS were injected using 31G needles. A cotton tip was used to press injected artery until the bleeding stopped (in about 10 min). The wound was then sutured, and the mouse was monitored until awake and moving normally. Spontaneous Bone Metastasis Assay BALB/c mice received mammary fat pad transplantation of 1-2 mm fragments of 2208L tumors or 5 3 10 5 4T1.2 cells suspended in 100 ml PBS. When tumors reached $1 cm 3 , surgical resection was used to remove the tumors. Mice were excluded from experiments if their tumor size was exceptionally large or small (2 SD from the group mean), or if the residual tumor signals were exceptionally strong after resection. The remaining mice were randomized into different treatment groups and closely monitored for 1 month (2208L) or 2 weeks (4T1.2) before being sacrificed. Immediately after euthanasia, hind limb bones (for 2208L and 4T1.2 models), spines (4T1.2), and lungs (4T1.2) were extracted for further analyses. In 2208L experiments, genomic DNA was purified from homogenized tissue. Quantitative PCR was then conducted using the primer sequences: 5 0 -CTCTGATGCCGCCGTGTT-3 0 and 5 0 -TGCCTCGTCTTGCA GTTCATT-3 0 to specifically detect cells with the p53-KO locus. The actin gene was used as the control. The relative quantity was calculated using the formula log 2 (10,000/DCt) (Eckhardt et al., 2005) . The Student's t test was used to compute the p value. See the rest of the animal study procedures in Supplemental Experimental Procedures.
Quantification of Cells in the Microenvironment Niche
Toluidine blue and TRAP staining were performed, and montaged images of the femur were taken and analyzed in the BCM bone Histomorphometry Core following standard procedures. We defined the microenvironment niche as the collection of stromal cells immediately adjacent to and directly contacting cancer cells, where there was neither discernible space between the plasma membranes of the two cells nor additional nucleus between the nuclei of the two cells.
Statistical Tests
Differences among growth curves were assessed using generalized linear models in the statmod package of the R statistical software. Values at growth curve time points were first converted to log scale to approximate the normal See also Figure S7 . n.s.
(legend on next page) distribution, and then used to derive the SD or 95% confidence interval of the mean using standard procedures. For other analyses, Student's t tests were used unless noted otherwise. Error bars SD.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Supplemental Experimental Procedures Animal Studies
Intra-cardiac injection and quantitation of disseminated cancer cells: intracardiac injection was performed as previously described (Minn et al., 2005) . At various time points, injected animals were euthanized. The hind limb bones were homogenized and subjected to genomic DNA extraction. Quantitative PCR was then used to determine the relative ratios of GFP-tagged and RFP-tagged cancer cells. The primer sequences were 5'-CCTCCTCCGAGGACGTCATCAA-3'
and 5'-ACAGGATGTCCCAGGCGAAG-3' for RFP, and 5'-AAGCTGACCCTGAAGTTCATCTGC-3' and 5'-CTTGTAGTTGCCGTCGTCCTTGAA-3' for GFP, respectively. Specifically, standard curves of ∆Ct values against cell numbers were made using in vitro cell suspensions. The curves were then used to gauge cell quantities in vivo.
Bioluminescence imaging: After injection, animals were imaged weekly using an IVIS Lumina II (Advanced Molecular Vision), following the manufacturer's recommended procedures and settings. We focused on bioluminescence signals at hind limbs. The acquired intensity data were divided over the Day 0 signal intensity of the same animal at the same locus to yield normalized values. For ex vivo bioluminescence signals, the intensity values were first normalized to Day 0 and then log-transformed before being plotted and subjected to statistical tests.
Pharmacological Treatment: Torin 1 was injected i.p. daily at the dosage of 6.8mg/kg.
Rapamycin was injected i.p. once every two days at the dosage of 4mg/kg. For antibody therapy, 4 mg/kg DECMA-1 (U3254; Sigma) or rat immunoglobulin G (IgG; I4131; Sigma) were injected i.p. twice a week via intraperitoneal injections. In the experiments using MCF-7 cells, estradiol tubes were prepared and transplanted to nude mice before cancer cell injection according to a previously published protocol (Robinson and Jordan, 1989 primary MSCs were extracted from Balb/c mice following the procedures described previously (Zhu et al., 2010) . The osteogenesis ability of MSCs was validated using protocols previously described (Reger et al., 2008) . All cells were maintained under the providers' recommended media. The PWIPZ system was used to introduce firefly luciferase fused with GFP or RFP into these cells using cancer cells and MSC/preOBs via lentivirus transduction. was added to the cultures to reach a final concentration of 150 µg/ml. For Renilla luciferase substrate Coelenterazine (CZ5, Goldbio), the working concentration was 2 µM. For each cell line, a standard curve was prepared between signal intensity and corresponding seeded cell numbers to validate the linear relationship between these variables. The organoid structures were visualized using an invert fluorescence microscope.
